Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

Comparative AAV Capsid Efficacy in Non-Human Primates

AAV CAPSID SELECTION: COMPARATIVE EFFICACY IN NHP MODELS

Comparative AAV Capsid Efficacy in Non-Human Primates

CELL & GENE | RNA | BIOLOGICS

Proven Intelligence in Preclinical AAV Vectorology.

Executive Summary

The selection of an optimal Adeno-Associated Virus (AAV) capsid directly influences the design and potential outcome of a therapeutic program. The choice between a clinically validated capsid (e.g., AAV8, AAV9) and a novel or engineered vector involves a strategic trade-off between regulatory precedence and potential performance gains. This analysis outlines how comparative efficacy studies in nonhuman primate (NHP) models provide the necessary data to de-risk this decision, ensuring the selection of a vector with the highest probability of clinical success. These head-to-head evaluations under GxP conditions are central to building a robust data package for multi-jurisdictional IND and IMPD submissions.

A senior scientist leads a discussion with a group of diverse junior scientists in a bright, modern laboratory setting.

Frequently Asked Questions

How do you determine the appropriate AAV capsid for IND-enabling toxicology studies in NHP models?

A standard template does not exist. The selection is a data-driven process tailored to the therapeutic goal. We evaluate the target tissue, desired expression levels, and potential immunogenicity. Often, this involves a comparative study design, testing a novel capsid against a clinically validated benchmark like AAV8 to quantify performance gains and establish a predictable safety profile.

What is the strategic value of testing a novel capsid against a well-characterized vector?

Testing a novel capsid against a benchmark provides the comparative data required by regulatory agencies. It demonstrates a clear, evidence-based rationale for selecting the new vector, such as superior tissue tropism or a more favorable immunogenicity profile. This comparative data is instrumental in justifying the move away from a vector with a more established clinical history.

How does capsid choice influence the design of preclinical programs and their timelines?

Capsid selection directly impacts study design, particularly for assessing non-target tissue biodistribution and immunogenicity. A novel capsid may require more extensive characterization. By leveraging our team’s deep historical expertise, we design efficient comparative studies that generate decisive data, keeping programs on an 18-24 month timeline to IND submission.

A close-up shot of a scientist in a lab coat and blue gloves using a micropipette to transfer a liquid sample into a small test tube.

Balancing Innovation with Regulatory Precedence

The development of next-generation therapies requires a disciplined approach to vector selection. Clinically validated capsids, such as AAV8 and AAVrh10, offer a significant advantage: a well-documented history of performance and safety in human trials. This provides a degree of predictability for biodistribution and immune response, which can streamline regulatory review.

Therapeutic goals may demand performance characteristics that these established vectors cannot provide. Novel and engineered capsids are designed to overcome specific limitations:

  • Enhanced Tissue Tropism: Directing the therapeutic payload specifically to the target organ or cell type.

  • Immune Evasion: Modifying the capsid surface to reduce recognition by pre-existing neutralizing antibodies.

  • Improved Transduction Efficiency: Achieving the desired therapeutic effect at a lower vector dose.

De-Risking Novel Capsids with NHP Comparative Studies

A direct comparative study in a relevant large animal model, particularly the nonhuman primate, is the definitive method for evaluating a novel capsid. By administering the novel vector alongside a benchmark capsid, program sponsors can generate clear, translatable data on relative performance.

This approach was validated in work demonstrating that certain novel capsids, like AAV3B, can achieve liver transduction efficiencies comparable to or exceeding established vectors like AAV8 (PMID: 26412589). Such studies provide the quantitative evidence needed to justify the selection of a new vector for liver-directed gene therapy. The translational impact of vector engineering is further supported by research showing that optimized payloads delivered by AAV can result in superior efficacy in disease models (PMID: 25023731).

“The AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption… Franklin Biolabs is an essential collaborator in our AAV-vector based gene therapy candidate development.”

  • Biotech Partner

Our scientific leadership has built a significant track record in this space. This history, which includes a 100% successful IND rate since 2019 for programs managed by our core team prior to Franklin Biolabs’ formal launch in 2024, is founded on designing these exact types of rigorous, decision-enabling studies. We structure these programs to align with harmonized international guidelines (ICH), supporting global regulatory submissions. For a deeper look into the infrastructure required, see our discussion on diversifying the value chain.

The data from these NHP studies directly informs the design of IND-enabling toxicology programs and provides a robust dataset for regulatory review.

This strategic investment in preclinical comparative analysis is a core component of minimizing clinical risk and accelerating the path to regulatory submission. For more information on our comprehensive capabilities, please see our main services page.

Preclinical | Translational Services

AAV Capsid Selection Strategy: Novel vs. Validated Vectors

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities